Content Conference Coverage Conferences INHSU 2016
INHSU 2016: Risk of Reinfection Is a Concern After Successful Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Created on Thursday, 22 September 2016 00:00
People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) -- achieving cure rates similar to those of the population as a whole -- but some people are reinfected with hepatitis C virus after being cured, suggesting that a greater emphasis on post-treatment prevention may be needed, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) this month in Oslo.
INHSU 2016: HCV Treatment Effective and May Work as Prevention for People Who Inject Drugs
- Details
- Category: HCV Treatment
- Created on Friday, 16 September 2016 00:00
Hepatitis C treatment for people who inject drugs is as safe and effective as it is for non-drug-users -- with cure rates exceeding 90% -- and treating enough of this population could reduce transmission or even bring a halt to local epidemics, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) last week in Oslo.
INHSU 2016: Scaling Up Treatment in Prisons Could Help Halt Hepatitis C Epidemics
- Details
- Category: HCV Treatment
- Created on Thursday, 08 September 2016 00:00
A substantial proportion of people with hepatitis C cycle through the criminal justice system, making prisons one of the most important settings for hepatitis C virus (HCV) prevention, testing, and treatment. Scaling up treatment could therefore play a major role in driving down HCV prevalence and curbing hepatitis C epidemics worldwide, according to studies presented at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) this week in Oslo.
INHSU 2016: Hepatitis C Vaccine Development Shows Progress but Scientific Barriers Remain
- Details
- Category: HCV Treatment
- Created on Sunday, 11 September 2016 00:00
An effective vaccine may be necessary to eliminate hepatitis C virus (HCV), but development has been hampered by several challenges including the variability of the virus and incomplete natural immunity, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) last week in Oslo. One promising prime-boost viral vector vaccine is currently in clinical trials.
INHSU 2016: Effective Antiviral Treatment Reduces Fatigue in People with Hepatitis C
- Details
- Category: HCV Treatment
- Created on Wednesday, 07 September 2016 00:00
Fatigue -- a common symptom among people living with hepatitis C virus (HCV) infection -- is associated with liver inflammation and fibrosis, but antiviral therapy that leads to a cure significantly reduces the likelihood of fatigue, according to a Danish study presented at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) this week in Oslo.
Web Design and Development by